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Introduction
Imaging techniques that allow the non-invasive assessment of 
disease processes at the molecular level have been developed for 
essentially all types of medical diagnostic imaging including ultra-
sound, magnetic resonance imaging, radionuclide/positron emis-
sion imaging, radiographic imaging, and optical imaging.1) The 
most common approach to molecular imaging has been to develop 
novel site-targeted contrast agents that are either activated by a 
disease-related process or are retained due to their adherence to 
disease-related molecules and are imaged after clearance of free 
tracer. For the diverse array of imaging technologies, there are 
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major differences between the detectors with regards to resolution, 
sensitivity, speed and cost. There are also important differences 
between the imaging probes used for different forms of imaging 
based on biodistribution, in vivo kinetics, temporal resolution, safe-
ty, and cost. No single form of molecular imaging is likely to fulfill 
the diverse needs of clinicians and biomedical scientists. Instead, 
there are certain applications where one type of molecular imag-
ing is likely to provide the most reasonable approach based on 
characteristics of the detector and imaging probe.
Molecular imaging with contrast-enhanced ultrasound (CEU) 
relies on the selective targeting and retention of encapsulated mi-
crobubbles (MB) or other acoustically-active particles to sites of 
disease.2) An ultrasound-based approach has several advantages 
and disadvantages compared to other forms of molecular imaging. 
One important limitation is that only events within the vascular 
space can be detected using targeted MBs with conventional size 
distribution. As is the case with all forms of molecular imaging 
with particle-based contrast agents, MB attachment is more com-
plex than a 1 : 1 binding profile between imaging probe and target 
molecule. Instead, MB attachment depends on a wide array of fac-
tors that include but are not limited to shear forces, the ligand on the 
MB surface, the targeted molecule, and bond kinetics. Advantages 
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of CEU molecular imaging are that it provides real-time informa-
tion, represents a good balance between spatial resolution and 
sensitivity, is portable is rapid, is widely available, and does not in-
volve non-ionizing radiation.2)3) In this review, we discuss some of 
the basic principles, and the most pertinent clinical applications 
where molecular imaging with ultrasound may have a major impact.
Molecular Targets for Cardiovascular Molecular 
Imaging
Ultrasound contrast agents to a large extent remain within the 
intravascular space.4) Accordingly, CEU molecular imaging is best 
suited for imaging disease processes that occur within the vascu-
lar compartment. There are several key pathobiologic processes 
that occur at the blood vessel-blood pool interface that are com-
mon to many cardiovascular diseases. They include: 1) endothelial 
cell activation and endothelial cell adhesion molecule (ECAM) ex-
pression, 2) leukocyte-endothelial interactions, and 3) thrombus 
formation and platelet adhesion. In this section we will discuss 
these targets for CEU molecular imaging that are used to provide 
information on disease development and progression in athero-
sclerosis, tissue ischemia, thrombosis, and angiogenesis.
Leukocytes and endothelial inflammatory adhesion molecules
Endothelial activation and leukocyte adhesion to the activated 
endothelium are hallmarks of the inflammatory process in cardio-
vascular disease.5)6) Fig. 1 shows the orchestrated processes that 
result in leukocyte recruitment in inflammation which include leu-
kocyte capture, rolling along the endothelial surface, adhesion, and 
transmigration across the endothelial boundary.7)8) The process of 
leukocyte recruitment is governed by the local generation of cyto-
kines and chemokines and the subsequent expression of ECAMs 
which interact with leukocyte counterligands.7)8) One of the key 
ECAMs involved in the initial inflammatory response are selectins 
(P- and E-selectin) which are a family of long adhesion molecules 
that extend beyond the endothelial glycocalyx and contribute pri-
marily to leukocyte capture and rolling by interacting with glyco-
protein counterligands that are constitutively expressed on leuko-
cytes.9) The selectin-mediated interactions can result in transient 
bond formation even in the face of high shear stress. The rolling of 
leukocytes exposes them to molecular signals that result in the ex-
pression of activated integrins which are heterodimeric molecules 
that interact with other ECAMs such as intercellular adhesion mol-
ecules (ICAMs) and vascular cell adhesion molecule-1 (VCAM-1). 
These integrin mediated interactions result in firm adhesion.7)
The wide array of adhesion molecules and the large library of li-
gands that have been created to detect or inhibit them have po-
tentiated CEU molecular imaging of inflammation. MBs have been 
targeted to either ECAMs or leukocyte adhesion molecules to de-
tect endothelial activation or leukocyte recruitment. Moreover, 
since different leukocyte subpopulations (neutrophils, monocyte 
subsets, etc.) are distinguished by specific cell surface markers, it 
has been possible to differentiate the type of inflammatory re-
sponses by targeting different cell surface markers. 
Thrombus formation
For imaging the fibrin component of thrombus, ultrasound con-
trast agents have been directly targeted to fibrin.10)11) This approach 
has not advanced rapidly because only recently have appropriate 
ligands that recognize only fibrin and do not bind plasma fibrinogen 
Leukocyte
P-selectin -----PSGL-1
E-selectin
VLA-4 -------------VCAM-1
Mac-1, LFA-1------ICAMsVascular lumen
Endothelium
Activation
Cytokines and chemokines
Selectin-mediated rolling
Integrin-mediated attachment
Capture                     Rolling                                Slow rolling                     Adhesion                    Transmigration
Fig. 1. Schematic illustrating mechanisms of leukocyte recruitment during inflammation. Key adhesion molecules involved in rolling and adhesion are 
shown. PSGL-1: P-selectin glycoprotein ligand-1, VCAM-1: vascular cell adhesion molecule-1, ICAM: intercellular adhesion molecule, VLA-4: very late anti-
gen-4, LFA-1: lymphocyte function-associated antigen-1.
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been developed. MBs have also been targeted to tissue factor in 
regions of vascular injury,10)12) which may provide a useful target 
for evaluating subclinical plaque rupture since tissue factor in in-
flamed plaques is ordinarily not available to binding by intravascu-
lar agents. Because of the pivotal role of platelets in thrombus for-
mation and in inflammation in cardiovascular diseases, and because 
of the availability of a wide array of ligands, CEU molecular imag-
ing of thrombus has more commonly been directed at platelets or 
platelet-binding processes. Similar to the inflammatory response, 
platelet adhesion and subsequent aggregation are mediated by a 
series of events that involve adhesion molecules. Under normal 
conditions, the endothelium plays an important role in preventing 
platelet adhesion through multiple mechanisms.13) Under situations 
of vascular inflammation or injury platelets adhere either through 
interactions with the endothelium, to monocytes, or to subendo-
thelial matrix in regions where endothelial integrity is lost.14) Al-
though the potential mediators of platelet adhesion are broad (Fig. 
2), CEU molecular imaging of platelet adhesion has focused on sev-
eral key molecular processes. The most common approach has been 
to target the glycoprotein IIb/IIIa (GPIIb/IIIa) integrin that is in-
volved in platelet adhesion and fibrinogen-mediated aggregation. 
Although arginine-glycine-aspartate (RGD)-containing peptides 
have been frequently used for targeting, the approach of using ac-
tivation-specific antibodies or antibody fragments on the MB sur-
face decreases non-specific interaction with non-activated circu-
lating platelets in the blood pool.15)16) The platelet GP1bα receptor 
plays a key role in platelet recruitment and rolling by interacting 
with a wide variety of ligands including activated von Willebrand 
factor (VWF) and leukocyte integrins.17) This receptor has also been 
targeted by conjugating molecules representing the GP1bα-binding 
domain of VWF to MBs.18) Recombinant GP1bα has also been con-
jugated to MBs to image VWF which can become active and form 
ultra-large multimers either by binding to subendothelial collagen, 
or on the endothelial surface in regions where shear stress is high 
or when regulatory proteases become inactive, such as in throm-
botic thrombocytopenic purpura and atherosclerosis.19)
Imaging angiogenesis
Angiogenesis (formation of new vessels), arteriogenesis (growth 
and remodeling of the arteriolar network), and development of 
large collaterals are important processes in either the pathogenesis 
or adaptive response to cardiovascular disease. Ultrasound molec-
ular imaging of vascular remodeling has relied on targeting MBs 
to some of the key processes that are detectable by an intravascu-
lar contrast agent. Targets have included specific endothelial inte-
grins expressed during neovascularization, such as αv-integrins, 
ECAMs that are upregulated during vascular activation and re-
modeling, growth factor receptors such as vascular endothelial 
growth factor-1 (VEGF-R1), and markers for the specific subset of 
inflammatory cells that are important in vascular remodeling.20-26) 
It is important to realize that not all forms of vascular remodeling 
utilize the same molecular mechanisms so that imaging targets 
will differ for compensatory angiogenesis that occurs in ischemic 
tissue and for adverse neovascularization that occurs in tumors or 
the vasa vasorum of plaques.
Targeted Contrast Agents
Microbubble contrast agents are gas-filled microspheres stabi-
lized by shells comprised of proteins, lipids or polymers.27) Signal 
generation occurs from either stable cavitation (volumetric oscilla-
tion) or inertial cavitation (destruction and dispersion) of MBs. The 
size of MBs that are conventionally used for cardiovascular or ra-
diology applications is generally in the range of 1 to 5 μm in diameter, 
Platelet
Platelet-binding
VWF multimers
Platelet                        Endothelium
P-selectin-----------------PSGL-1
PSGL-1-----------------P-selectin
GP1b-------------------P-selectin
GPIIb/IIIa--------Fbgn--------αγβ3
GPIIb/IIIa-------Fbgn------ICAM-1
CD40L----------------------CD40
Platelet                                    VWF
GP1bα----------------A1 domain
GPIIb/IIIa--------------C1 domain
Platelet                            Monocyte
P-selectin-----------------PSGL-1
GP1bα---------------------Mac-1
GPIIb/IIIa-------Fbgn-------Mac-1
CD40L----------------------CD40
Endothelium
Weibel-Palade body
Platelet-endothelial Platelet-VWF Platelet-monocyte
Fig. 2. Schematic illustrating potential mechanisms of platelet adhesion in cardiovascular disease. PSGL-1: P-selectin glycoprotein ligand-1, ICAM: inter-
cellular adhesion molecule, VWF: von Willebrand factor. GP1bα: glycoprotein Ib-alpha, GpIIb/IIIa: glycoprotein IIb/IIIa.
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which permits their intravenous injection and free passage through 
the microcirculation of the pulmonary and peripheral circulation. 
It should be noted that smaller non-MB contrast agents such as 
echogenic liposomes and liquid-core emulsion agents, some of which 
can undergo phase-transition to gaseous bodies, have also been 
developed and are being investigated for potential extravascular 
targeting. 
Targeting of MBs have been accomplished using two general 
approaches (Fig. 3). One strategy relies on non-specific attachment 
of MBs to activated leukocytes and even endothelial cells via opso-
nization. This process is mediated by complement activation and 
deposition on the shell surface, especially for lipid-shelled MBs.28-30) 
Opsonization is also probably responsible in part for their clear-
ance by the reticuloendothelial organs but can also mediate bind-
ing to cells with complement receptors. Amplification of this 
process can be achieved by chemical modification of lipid shell 
components such as adding phosphatidylserine.28-30) A more spe-
cific targeting approach involves attachment of targeting ligands 
(antibodies, peptides, glycoproteins, etc.) to the surface of MBs us-
ing any number of chemical conjugation strategies. This method 
allows characterization of the upregulation of specific adhesion 
molecules or recruitment of specific cellular populations. Success-
ful site-targeted imaging relies on many considerations (Fig. 4) in-
cluding the density and binding kinetics of the targeting ligands; 
surface concentration and availability of the target molecule; and 
the specificity of the ligand for the target, and the target for the 
disease process of interest.31)
Molecular Imaging Protocols
The aim of CEU molecular imaging is to detect signal from tar-
geted MBs that are retained in tissue due to their selective adher-
ence to target molecules. The most commonly used approach, il-
lustrated in Fig. 5, involves single bolus injection of agent and then 
delaying imaging of retained MBs until there is sufficient clearance 
of freely circulating MBs from the blood pool.30) Clearance gener-
ally requires 5-10 minutes depending on the type and dose of MB, 
the tissue of interest, and the animal species.29) The signal intensity 
in the initial frame on resumption of imaging reflects the total tis-
sue concentration of both retained MBs and the small amount of 
freely circulating MBs that remain.29)30) The signal contribution 
from the circulating component can then be calculated by acoustic 
destruction of MBs and evaluating degree of signal replenishment 
over the course of several seconds. The difference between the re-
plenishment signal and that on the initial frame(s) represents sig-
nal component from retained agent. It should be noted that suc-
cessful molecular imaging depends on in vivo stability of MBs over 
the period from injection to imaging. Stability can be influenced by 
the size (faster removal for larger particles) and composition of the 
ultrasound contrast agent. In general, signal from retained MBs 
has been quantified as video intensity within a defined region-of-
interest. This approach works best when imaging MB retention 
within the microcirculation of an organ. When quantifying signal 
at the endothelial surface of large vessel, defining a region-of-in-
terest is more difficult for detecting MBs due to the thin layer of 
contrast and specular reflection, which has created the need for 
innovative approaches to imaging.
Fig. 3. Strategies used for targeting of microbubble contrast agents.
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Fig. 4. Determinants of the success of ligand-directed targeting of microbubbles contrast agents.
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Cardiovascular Applications for Ultrasound 
Molecular Imaging  
Atherosclerosis
The pathophysiology of atherosclerosis is diverse, complex, and 
changes over the decades between disease inception and clinical 
events. Although the changing molecular environment provides 
many potential targets for molecular imaging, the selection of the 
target must be guided by the stage of disease and intended clinical 
use. For example, evaluation for a “vulnerable plaque” or “vulnera-
ble patient” defined as heightened susceptibility to acute athero-
thrombotic complication is best accomplished by imaging the spe-
cific processes that lead to plaque rupture or thrombotic occlusion. 
These events may include platelet adhesion, endothelial activation, 
macrophage activity, or protease activity.32) In contrast, assessing 
very early disease is likely to rely on imaging the accumulation of 
Fig. 5. Schematic illustrating a common algorithm for molecular imaging 
with targeted MB contrast agents.
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Fig. 6. CEU molecular imaging of endothelial activation and platelet adhesion in the aorta in a murine model of age-dependent atherosclerosis (LDL-/-, 
ApoBec-1-/-), and the effect of anti-oxidant therapy with the NADPH-oxidase-inhibitor apocynin at high or low dose. A-D: molecular imaging signal of P-
selectin, VCAM-1, GP1bα, and control MBs in mice at 30 weeks of age and at 40 weeks of age with and without treatment with apocynin. Thoracic aorta 
images from a non-treated 40 weeks mouse are shown with high-frequency 2-D ultrasound (E) and CEU molecular imaging with GP1bα-targeted and 
control MBs (F and G).18) CEU: contrast-enhanced ultrasoud, NADPH: nicotinamide adenine dinucleotide phosphate, MB: microbubble, VCAM-1: vascular 
cell adhesion molecule-1, WT: wild-type mice, DKO: double knockout mice, LDL: low-density lipoprotein, 2-D: 2-dimensional.
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oxidized lipids or ECAM expression. Ultrasound molecular imaging 
has been used to primarily detect the processes that occur at the 
endothelial-blood pool interface. 
For in vivo molecular imaging of endothelial activation, MBs tar-
geted to adhesion molecules such as P-selectin, ICAM-1, and 
VCAM-1 have been applied. CEU imaging with these agents have 
been used in murine models to not only detect advanced high-risk 
plaques, but also the earliest stages of endothelial activation even 
before development of significant neo-intimal formation.33-35) In 
murine models, imaging of VCAM-1 has also been shown to pro-
vide readout of diet-induced changes in the degree of plaque in-
flammatory activity.35) More recently, targeted imaging of VCAM-1 
and P-selectin have successfully been performed in non-human 
primate models of atherosclerosis.36) In these studies, early endo-
thelial activation associated with obesity and insulin resistance 
could be detected about a year before any significant increase in 
intima-medial thickness. Several studies have also suggested that 
very high-risk atherosclerotic disease may not need sophisticated 
targeting strategies. Non-specific retention of lipid and albumin 
MBs, presumably through interactions with the activated vascular 
endothelium, has been used to detect atherosclerotic disease in 
animal models.37) With regards to its application in pre-clinical 
drug development, CEU molecular imaging of ECAM expression in 
atherosclerosis has also been used to evaluate the therapeutic im-
pact of emerging therapies. For example, CEU molecular imaging 
has been used to evaluate how new anti-oxidants that inhibit nic-
otinamide adenine dinucleotide phosphate oxidase can reduce 
plaque inflammation and thrombosis (Fig. 6).18)
Imaging of thrombus, activated platelets, and von Willebrand 
factor
Thrombosis plays a major role in many pathophysiologic pro-
cesses in cardiovascular disease. Accordingly, there are is interest 
in using targeted imaging to enhance the detection of large 
thrombi within vessels or the cardiac chamber, microvascular 
thrombosis such as that which occurs with microvascular no-re-
flow, or a pro-thrombotic environment such in the region of a 
high-risk atherosclerotic plaque. It should also be noted that so-
nothrombolysis, the acoustic disruption of clot, is accelerated by 
MB cavitation and that thrombus-targeted MBs can further im-
prove this therapy.38)
Imaging of the pro-thrombotic environment has been achieved 
by targeting MBs to a wide variety of ligands. Echogenic liposomes 
have been targeted to both tissue factor and fibrin in animal models 
of atherosclerosis.10)12) A more common approach has been to image 
platelets which play a major role in acute coronary syndromes by 
targeting the GPIIb/IIIa receptor through surface conjugation of 
either RGD-peptides or antibodies (whole or fragments), or the 
platelet GP1bα receptor by surface conjugation of a peptide repre-
senting the A1 binding domain of VWF.15)16)18) By targeting GPIIb/IIIa 
it is has been possible to use CEU molecular imaging to monitor 
thrombolysis in animal models of carotid thrombosis.16) By targeting 
GP1bα it has been possible to image the low level of platelet-endo-
thelial interactions that contribute to the conversion of a plaque to 
unstable phenotype.18) Recently, CEU molecular imaging with MBs 
bearing recombinant GP1bα has been used to definitively demon-
strate the presence of dysregulated VWF on the surface of athero-
sclerotic plaques.19) These data are important since they have pro-
vided insight into new mechanisms by which oxidative stress leads 
to a pro-atherothrombotic environment.
Tissue ischemia
Ischemic memory imaging refers to non-invasive visualization 
of molecular events that occur with ischemia but that can persist 
for hours after restoration of normal perfusion. This approach is 
clinically important because it allows after-the-fact recognition of 
ischemic insult even in the absence of infarction. This approach 
may also be particularly useful for diagnosing active ischemia in 
patients who have preexisting wall motion abnormalities and per-
fusion defects from prior events.39) An ultrasound approach to 
ischemic memory imaging is attractive because of the speed and 
portable nature of CEU molecular imaging.
Molecular imaging of ischemia was first achieved with anionic 
MBs bearing phosphatidylserine which allowed detection of post-
ischemic inflammatory cell recruitment.40) More recently, selectin 
targeting has been used involving MBs bearing either mAb against 
P-selectin, sialyl lewis-X residues, or a recombinant form of the 
endogenous selectin counterligand P-selectin glycoprotein li-
gand-1 (PSGL-1).33)41)42) P-selectin is an ideal target since it is pre-
stored within endothelial Weibel-Palade bodies, is released very 
rapidly after ischemia, and persists for hours after resolution of 
ischemia. By using PSGL-1 as a targeting moiety, it has been possi-
ble to also image later phase E-selectin expression which may help 
extend the post-ischemic window for successful CEU ischemic 
memory imaging.41) Imaging of selectin expression has been shown 
in murine models and in non-human primates to detect myocardi-
al ischemic insult without infarction long after post-ischemic 
stunning has resolved (Fig. 7).41)42)
Molecular imaging of vascular remodeling 
Vascular remodeling in the form vasculoneogenesis plays a det-
rimental role in atherosclerosis; and in the form of angiogenesis 
and arteriogenesis plays a compensatory role to prevent ischemic 
complications in chronic severe coronary artery disease and 
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peripheral arterial disease.43) Vascular remodeling is a complex pro-
cess involving multiple different biologic triggers, signaling path-
ways, and cellular responses.44)45) Perfusion imaging alone is an 
attractive method for ultimately determining the end-result of 
adaptive vascular remodeling in ischemic disease. However, molec-
ular imaging is thought to be an important research tool for un-
derstanding the biologic processes and possibly for rapid evalua-
tion of the effect of new pro-angiogenic therapies. The endothelial 
molecular targets for CEU molecular imaging have been tailored for 
the specific cells and processes involved. CEU molecular imaging 
of endothelial activation specific to angiogenesis has involved im-
aging the αv-integrin family of adhesion molecules.20-22) Using this 
approach in a model of hindlimb ischemia, it has been possible to 
detect vascular remodeling that occurs even prior to detectable 
changes in perfusion. Because of the link between inflammation 
and angiogenesis, molecular imaging of the cellular inflammatory 
response can also be used to detect angiogenic processes. Recent-
ly, CEU molecular imaging has been used to evaluate the paracrine 
effects of stem cell therapy in ischemic limb disease.25) These stud-
ies demonstrated that certain adult progenitor cells act through 
endothelial activation and recruitment of a specific population of 
pro-angiogenic monocytes. Although targeted MBs to VEGF recep-
tors have been developed for tumor microvascular imaging, they 
have not been extensively used to examine ischemia-related re-
modeling.46)
Future Perspectives
Techniques for molecular imaging with ultrasound have been 
developed on the premise that these techniques will positively im-
pact patient outcomes. They may do so by providing earlier diag-
nosis of disease, by providing a more definitive diagnosis of dis-
ease, or by guiding appropriate therapy by defining the active 
molecular processes in any given patients (so called “personalized 
treatment”). With these lofty goals in mind, most of the progress 
that has occurred in the field has been limited to the creation of 
new targeted MB agents and testing their performance in animal 
models of disease. The transition to using these agents in humans 
is predicated on several key steps. The most important step is to 
identify applications where molecular imaging will provide the 
most incremental benefit to existing care paradigms. For any CEU 
molecular imaging application, it is then necessary to identify the 
best ligand for selective targeting and to define the most appropri-
ate conjugation chemistry for MB surface coupling with regards to 
safety and ligand density. Finally, after safety and proof of concept 
studies are performed, there needs to be confirmation that appli-
cation of molecular imaging technology can substantially improve 
outcomes and/or reduce healthcare costs. Although we are far off 
from agency approval of any ultrasound-based molecular imaging 
agent, it is reassuring that even today CEU molecular imaging is 
having a positive impact through its use in cardiovascular research 
to discover new pathophysiologic processes and as a biologic 
readout to test new therapeutic agents.
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